Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update

Author's Avatar
May 12, 2022

Virios+Therapeutics%2C+Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced financial results for the first quarter ended March 31, 2022.